Literature DB >> 19442432

False positive autoantibodies to glutamic acid decarboxylase in opsoclonus-myoclonus-ataxia syndrome after intravenous treatment with immunoglobulin.

F de Beer, M W J Schreurs, E M J Foncke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19442432     DOI： 10.1016/j.clineuro.2009.03.010

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN： 0303-8467            Impact factor:   1.876


× No keyword cloud information.
  5 in total

Review 1.  Presentation of opsoclonus myoclonus ataxia syndrome with glutamic acid decarboxylase antibodies.

Authors:  Hanul Srinivas Bhandari
Journal:  BMJ Case Rep       Date:  2012-08-08

2.  Detection of anti-glutamic acid decarboxylase antibodies in immunoglobulin products.

Authors:  Tukisa D Smith; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2017-06-29

3.  Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity.

Authors:  Thomas Grüter; Anthonina Ott; Wolfgang Meyer; Sven Jarius; Markus Kinner; Jeremias Motte; Kalliopi Pitarokoili; Ralf Gold; Lars Komorowski; Ilya Ayzenberg
Journal:  J Neurol       Date:  2019-11-14       Impact factor: 4.849

4.  Detection of Antibodies Against Human Leukocyte Antigen Class II in the Sera of Patients Receiving Intravenous Immunoglobulin.

Authors:  Hiroyuki Takamatsu; Shinya Yamada; Noriaki Tsuji; Noriharu Nakagawa; Erika Matsuura; Atsuo Kasada; Keijiro Sato; Kohei Hosokawa; Noriko Iwaki; Masahisa Arahata; Hidenori Tanaka; Shinji Nakao
Journal:  Transplant Direct       Date:  2021-05-18

5.  Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice.

Authors:  Maria M Dimitriadou; Haris Alexopoulos; Sofia Akrivou; Eleni Gola; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.